Online citations, reference lists, and bibliographies.

High-throughput Screens Identify MicroRNAs Essential For HER2 Positive Breast Cancer Cell Growth.

Suvi-Katri Leivonen, K. Sahlberg, R. Mäkelä, E. U. Due, O. Kallioniemi, A. Børresen-Dale, M. Perälä
Published 2014 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
MicroRNAs (miRNAs) are non-coding RNAs regulating gene expression post-transcriptionally. We have characterized the role of miRNAs in regulating the human epidermal growth factor receptor 2 (HER2)-pathway in breast cancer. We performed miRNA gain-of-function assays by screening two HER2 amplified cell lines (KPL-4 and JIMT-1) with a miRNA mimic library consisting of 810 human miRNAs. The levels of HER2, phospho-AKT, phospho-ERK1/2, cell proliferation (Ki67) and apoptosis (cPARP) were analyzed with reverse-phase protein arrays. Rank product analyses identified 38 miRNAs (q < 0.05) as inhibitors of HER2 signaling and cell growth, the most effective being miR-491-5p, miR-634, miR-637 and miR-342-5p. We also characterized miRNAs directly targeting HER2 and identified seven novel miRNAs (miR-552, miR-541, miR-193a-5p, miR-453, miR-134, miR-498, and miR-331-3p) as direct regulators of the HER2 3'UTR. We demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases). miR-342-5p specifically inhibited HER2-positive cell growth, as it had no effect on the growth of HER2-negative control cells in vitro. Furthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts. In conclusion, we have identified miRNAs which are efficient negative regulators of the HER2 pathway that may play a role in vivo during breast cancer progression. These results give mechanistic insights in HER2 regulation which may open potential new strategies towards prevention and therapeutic inhibition of HER2-positive breast cancer.
This paper references
10.1158/0008-5472.CAN-08-2920
microRNA-205 regulates HER3 in human breast cancer.
M. Iorio (2009)
10.1073/pnas.0510565103
A microRNA expression signature of human solid tumors defines cancer gene targets
S. Volinia (2006)
10.1073/pnas.0803230105
A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence
J. Forman (2008)
10.1093/bioinformatics/18.suppl_1.S96
Variance stabilization applied to microarray data calibration and to the quantification of differential expression
W. Huber (2002)
10.1186/gb-2006-7-7-r66
Analysis of cell-based RNAi screens
M. Boutros (2006)
10.1038/onc.2009.445
Regression of murine lung tumors by the let-7 microRNA
Phong Trang (2010)
10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
10.1038/nature04303
Silencing of microRNAs in vivo with ‘antagomirs’
Jan Krützfeldt (2005)
10.1073/pnas.0803304105
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
J. Foekens (2008)
10.5858/arpa.2013-0953-SA
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
A. Wolff (2014)
10.1038/nature06487
Endogenous human microRNAs that suppress breast cancer metastasis
S. Tavazoie (2008)
10.1016/j.ccr.2009.04.004
PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
N. Hynes (2009)
10.3109/0284186X.2012.713508
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Marit Synnestvedt (2013)
10.1038/nature07299
MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation
Y. Tay (2008)
10.1186/1476-4598-9-317
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Diana M. Cittelly (2010)
10.1371/journal.pone.0016915
miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors
E. Enerly (2011)
10.1126/scitranslmed.3003601
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis
Y. Yao (2012)
10.1158/0008-5472.CAN-10-0655
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.
Jason F. Wiggins (2010)
10.1038/nrg3162
MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship
Amy E Pasquinelli (2012)
10.1038/nrclinonc.2011.177
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga (2012)
10.1074/jbc.M109.030098
miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer*
Michael R. Epis (2009)
10.1016/j.ctrv.2009.12.007
17q12-21 - the pursuit of targeted therapy in breast cancer.
Ronan W Glynn (2010)
10.1016/j.cell.2009.04.021
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Janaiah Kota (2009)
10.1074/jbc.M609383200
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b*
G. Scott (2007)
10.1038/nature12108
The shaping and functional consequences of the microRNA landscape in breast cancer
H. Dvinge (2013)
10.1016/j.ceb.2008.12.010
ErbB receptors and signaling pathways in cancer.
N. Hynes (2009)
10.1158/0008-5472.CAN-05-1783
MicroRNA gene expression deregulation in human breast cancer.
M. Iorio (2005)
10.1038/sj.bjc.6690114
Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6
J. Kurebayashi (1999)
10.1186/bcr2257
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer
A. Lowery (2008)
10.1101/gr.082701.108
Most mammalian mRNAs are conserved targets of microRNAs.
Robin C Friedman (2009)
10.1016/j.bbrc.2011.07.033
ErbB2 down-regulates microRNA-205 in breast cancer.
Ryohei Adachi (2011)
10.1016/j.cell.2007.10.054
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
F. Yu (2007)
10.1158/0008-5472.CAN-10-2421
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.
Päivi Östling (2011)
10.1038/nature06783
LNA-mediated microRNA silencing in non-human primates
J. Elmén (2008)
10.1158/0008-5472.CAN-05-0553
Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.
Q. Pan (2005)
10.1038/mt.2009.207
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.
Fumitaka Takeshita (2010)
10.1016/J.CCR.2007.08.030
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
K. Berns (2007)
10.1038/msb.2011.100
Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer
Stefan Uhlmann (2012)
10.1200/JCO.2006.09.2775
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
10.1016/j.molonc.2012.10.012
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.
Kristine Kleivi Sahlberg (2013)
10.1016/j.molcel.2010.03.007
Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures.
John S. Tsang (2010)
10.1158/0008-5472.CAN-06-3936
Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.
Alessandra Magnifico (2007)
10.1093/nar/gkn342
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
R. Juliano (2008)
10.1073/pnas.0703820104
Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR
J. R. Lytle (2007)
10.1016/j.jconrel.2012.05.015
Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
Shuang Dou (2012)
10.1016/j.cell.2009.03.047
RETRACTED: A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis
Scott Valastyan (2009)
10.1038/onc.2009.241
Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines
S-K Leivonen (2009)
10.1093/nar/gkm952
miRBase: tools for microRNA genomics
S. Griffiths-Jones (2008)
10.1093/bioinformatics/17.4.369
J-Express: exploring gene expression data using Java
B. Dysvik (2001)



This paper is referenced by
10.18632/oncotarget.7577
A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth
Yogin Patel (2016)
10.1186/s13058-015-0526-y
Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management
Eleni van Schooneveld (2015)
10.1186/s13046-020-01622-x
Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”
Katia Grillone (2020)
10.1186/s13046-017-0649-3
Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel
Zhan Yang (2017)
10.1038/bjc.2014.113
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
M. K. Nygren (2014)
10.3390/jcm4081578
MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression
Merav Kedmi (2015)
10.1038/onc.2014.419
Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1
T. Que (2015)
MiR-199 b-5 p suppresses proliferation and invasion of non-small cell lung cancer ( NSCLC ) via HER 2 / PI 3 K / Akt pathway
Weijun Chen (2016)
10.1002/jcp.25813
The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.
Afsane Bahrami (2018)
10.1007/s13277-016-4988-z
MicroRNA: a connecting road between apoptosis and cholesterol metabolism
Yogita K Adlakha (2016)
10.1007/978-1-4939-7493-1_4
MicroRNA Networks in Breast Cancer Cells.
Andliena Tahiri (2018)
10.1038/srep30923
MicroRNA-491 regulates the proliferation and apoptosis of CD8+ T cells
Ting Yu (2016)
10.1016/j.clinbiochem.2018.07.008
A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance.
Emmanuel I. Papadopoulos (2018)
10.1002/cam4.1491
miR‐541 suppresses proliferation and invasion of squamous cell lung carcinoma cell lines via directly targeting high‐mobility group AT‐hook 2
L. Xu (2018)
10.1016/j.bbrc.2018.03.059
A potential risk factor of essential hypertension in case-control study: Circular RNA hsa_circ_0037911.
Xingjie Bao (2018)
10.1007/s11523-017-0476-7
Exploiting microRNAs As Cancer Therapeutics
T. Robb (2017)
10.18632/ONCOTARGET.3759
MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells
James N Fisher (2015)
10.1109/BIBM.2015.7359678
Predicting microRNA-disease associations by integrating multiple biological information
W. Lan (2015)
10.3389/fonc.2017.00101
No Functional Role for microRNA-342 in a Mouse Model of Pancreatic Acinar Carcinoma
James Dooley (2017)
10.1016/j.yexcr.2018.01.026
Primate‐specific miRNA‐637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression
R. Xu (2018)
10.7314/APJCP.2015.16.7.2591
Recent progress in HER2 associated breast cancer.
Wei-jia Wang (2015)
10.3892/ijmm.2016.2797
Sevoflurane inhibits the migration and invasion of glioma cells by upregulating microRNA-637.
Wenbo Yi (2016)
10.3892/etm.2019.8061
Downregulation of miR-552 in hepatocellular carcinoma inhibits cell migration and invasion, and promotes cell apoptosis via RUNX3
Ying Ma (2019)
10.1002/1878-0261.12700
Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2.
Qian Zhou (2020)
10.12659/MSM.909229
Circular RNA hsa-circ-0012129 Promotes Cell Proliferation and Invasion in 30 Cases of Human Glioma and Human Glioma Cell Lines U373, A172, and SHG44, by Targeting MicroRNA-661 (miR-661)
Gang Xie (2018)
10.1016/j.pharmthera.2016.11.012
MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction
Farah Nassar (2017)
Development of nanoparticle platform for therapeutic siRNA and drug delivery to breast cancer
Worapol Ngamcherdtrakul (2015)
10.1016/j.molonc.2015.03.001
MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
Anna Aakula (2015)
10.1002/mgg3.1136
SCD rs41290540 single‐nucleotide polymorphism modifies miR‐498 binding and is associated with a decreased risk of coronary artery disease
Zhou Liu (2020)
10.1186/s12943-015-0464-4
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
Marijn T. M. van Jaarsveld (2015)
MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo.
X. Peng (2014)
10.18419/opus-2350
miRNAs in control of oncogenic signaling in breast cancer cells
Annabell Bischoff (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar